How to buy VistaGen Therapeutics stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VistaGen Therapeutics stock

Own VistaGen Therapeutics stock in just a few minutes.

VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 11 staff and has a trailing 12-month revenue of around USD$647,600.

How to buy shares in VistaGen Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for VistaGen Therapeutics. Find the stock by name or ticker symbol: VTGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VistaGen Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of VistaGen Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of VistaGen Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

VistaGen Therapeutics share price

Use our graph to track the performance of VTGN stocks over time.

VistaGen Therapeutics shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$0.35 - USD$3.18
50-day moving average USD$2.2806
200-day moving average USD$1.4888
Wall St. target priceUSD$5.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.829

Buy VistaGen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VistaGen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VistaGen Therapeutics financials

Revenue TTM USD$647,600
Gross profit TTM USD$0
Return on assets TTM -16.34%
Return on equity TTM -30.49%
Profit margin 0%
Book value $0.676
Market capitalisation USD$314.8 million

TTM: trailing 12 months

Shorting VistaGen Therapeutics shares

There are currently 9.2 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 8.5% up from 8.5 million last month.

There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.

VistaGen Therapeutics's "short interest ratio" (SIR)

VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 5.7 million). VistaGen Therapeutics's SIR currently stands at 1.63. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 1630 shares are currently held short.

However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0644% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 64 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.

Find out more about how you can short VistaGen Therapeutics stock.

VistaGen Therapeutics share dividends

We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.

Have VistaGen Therapeutics's shares ever split?

VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.

VistaGen Therapeutics share price volatility

Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.35 up to $3.18. A popular way to gauge a stock's volatility is its "beta".

VTGN.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8174. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).

VistaGen Therapeutics overview

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site